Literature DB >> 16091741

Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs.

Emma K Baker1, Ricky W Johnstone, John R Zalcberg, Assam El-Osta.   

Abstract

The mechanism of action of chemotherapeutic drugs and their ability to induce multidrug resistance (MDR) are of relevance to cancer treatment. Overexpression of P-glycoprotein (Pgp) encoded by the MDR1 gene following chemotherapy can severely limit the efficacy of anticancer agents; however, the manner by which cells acquire high levels of Pgp has not been defined. Herein, we demonstrate that chemotherapeutic drugs induce specific epigenetic modifications at the MDR1 locus, concomitant with MDR1 upregulation mediated by transcriptional activation, and a potential post-transcriptional component. We have established that the mechanisms are not mutually exclusive and are dependent on the methylation state of the MDR1 promoter. MDR1 upregulation did not result in further changes to the CpG methylation profile. However, dramatic changes in the temporal and spatial patterning of histone modifications occurred within the 5' hypomethylated region of MDR1, directly correlating with MDR1 upregulation. Specifically, drug-induced upregulation of MDR1 was associated with increases in H3 acetylation and induction of methylated H3K4 within discrete regions of the MDR1 locus. Our results demonstrate that chemotherapeutic drugs can actively induce epigenetic changes within the MDR1 promoter, and enhance the MDR phenotype.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16091741     DOI: 10.1038/sj.onc.1208955

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  67 in total

1.  Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance.

Authors:  Hairong Huo; Pellegrino G Magro; E Christy Pietsch; Brijesh B Patel; Kathleen W Scotto
Journal:  Cancer Res       Date:  2010-09-22       Impact factor: 12.701

Review 2.  Biology and Treatment of Rhabdoid Tumor.

Authors:  James I Geller; Jacquelyn J Roth; Jaclyn A Biegel
Journal:  Crit Rev Oncog       Date:  2015

3.  A novel role for BDNF-TrkB in the regulation of chemotherapy resistance in head and neck squamous cell carcinoma.

Authors:  Junegoo Lee; Tilahun Jiffar; Michael E Kupferman
Journal:  PLoS One       Date:  2012-01-20       Impact factor: 3.240

4.  Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol).

Authors:  Hratch Arbach; Viktor Viglasky; Florence Lefeu; Jean-Marc Guinebretière; Vanessa Ramirez; Nadège Bride; Nadia Boualaga; Thomas Bauchet; Jean-Philippe Peyrat; Marie-Christine Mathieu; Samia Mourah; Marie-Pierre Podgorniak; Jean-Marie Seignerin; Kenzo Takada; Irène Joab
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

5.  DNA methylation of circulating DNA: a marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients.

Authors:  Gayatri Sharma; Sameer Mirza; Rajinder Parshad; Siddartha Datta Gupta; Ranju Ralhan
Journal:  Tumour Biol       Date:  2012-06-29

Review 6.  Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy.

Authors:  David S Miller; Björn Bauer; Anika M S Hartz
Journal:  Pharmacol Rev       Date:  2008-06-17       Impact factor: 25.468

7.  Epigenetic changes associated with inflammation in breast cancer patients treated with chemotherapy.

Authors:  Alicia K Smith; Karen N Conneely; Thaddeus W W Pace; Donna Mister; Jennifer C Felger; Varun Kilaru; Mary J Akel; Paula M Vertino; Andrew H Miller; Mylin A Torres
Journal:  Brain Behav Immun       Date:  2014-02-28       Impact factor: 7.217

8.  Role of the highly structured 5'-end region of MDR1 mRNA in P-glycoprotein expression.

Authors:  Rebecca A Randle; Selina Raguz; Christopher F Higgins; Ernesto Yagüe
Journal:  Biochem J       Date:  2007-09-15       Impact factor: 3.857

9.  Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance.

Authors:  Eran E Bram; Michal Stark; Shachar Raz; Yehuda G Assaraf
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

10.  Functional crosstalk between type I and II interferon through the regulated expression of STAT1.

Authors:  Daniel J Gough; Nicole L Messina; Linda Hii; Jodee A Gould; Kanaga Sabapathy; Ashley P S Robertson; Joseph A Trapani; David E Levy; Paul J Hertzog; Christopher J P Clarke; Ricky W Johnstone
Journal:  PLoS Biol       Date:  2010-04-27       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.